The short version of peptide degradation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
== Precautions == An equianalgesic chart can be a useful tool, but the user must take care to correct for all relevant variables such as route of administration, cross tolerance, half-life and the bioavailability of a drug. For example, the narcotic levorphanol is 4–8 times stronger than morphine, but also has a much longer half-life. Simply switching the patient from 40 mg of morphine to 10 mg of levorphanol would be dangerous due to dose accumulation, and hence frequency of administration should also be taken into account. There are other concerns about equianalgesic charts. Many charts derive their data from studies conducted on opioid-naive patients. Patients with chronic (rather than acute) pain may respond to analgesia differently. Repeated administration of a medication is also different from single dosing, as many drugs have active metabolites that can build up in the body. Patient variables such as sex, age, and organ function may also influence the effect of the drug on the system. These variables are rarely included in equianalgesic charts.
Salvinorin B ethoxymethyl ether, also known as 2-O-ethoxymethylsalvinorin B (2-EMSB) or as symmetry, is a semi-synthetic analogue of the natural product salvinorin A, the psychoactive chemical in Salvia Divinorum, with a longer duration of action of around 3 hours (compared to less than 30 minutes for salvinorin A), and increased affinity and intrinsic activity at the κ-opioid receptor. Like the related compound herkinorin, 2-EMSB is made from salvinorin B, which is most conveniently made from salvinorin A by deacetylation, as while both salvinorin A and salvinorin B are found in the plant Salvia divinorum, salvinorin A is present in larger quantities. 2-EMSB has an affinity (Ki) of 0.32 nM at the κ-opioid receptor, and around 3,000 times selectivity over the μ- and δ-opioid receptors, making it one of the most potent and selective κ-opioid receptor agonists yet discovered. In animal studies it fully substituted for salvinorin A and the synthetic κ-opioid receptor agonist U-69593, and was active at doses as low as 0.005 mg/kg. Human bioassays found the compound to be active at 50 μg smoked. It has been sold online as an analytical standard.
A mostly separate set of diseases called thalassemias involves underproduction of normal and sometimes abnormal hemoglobins, through problems and mutations in globin gene regulation. All these diseases produce anemia.
Intra-articular steroid injections often help with treatment in oligoarticular JIA. Conventional synthetic DMARDs, such as methotrexate are a first-line therapy, and biologic DMARDs such as TNF-α inhibitors may be added on for refractory cases. Rheumatoid factor-negative polyarticular JIA (15-20% of all JIA cases) can be treated with synthetic conventional DMARDs (such as methotrexate), with biologic DMARDs (such as TNF inhibitors) being a second-line add-on treatment option. Rheumatoid factor-positive JIA (5% of JIA cases, and also being rare in children younger than 9-years old) is associated with a poor prognosis, and early treatment is required to prevent significant joint destruction and disability. It is very similar pathologically to adult rheumatoid arthritis. Synthetic conventional DMARDs or biologic DMARDs are standard therapy for this type of JIA. Enthesitis-related arthritis is a type of JIA characterized by enthesitis; inflammation of the area where tendons and ligaments attach to bone. NSAIDs are commonly used for symptomatic relief, with the anti-inflammatories sulfasalazine and TNF inhibitors also being used. Biologic DMARDs such as TNF-α inhibitors are used for sacroilitis (inflammation of the sacroiliac joint). IL-17 inhibitors are used for refractory disease. 40-60% of children with enthesitis-related variant of JIA have involvement of the axial skeleton, including sacroiliitis, spondyloarthritis, and ankylosing spondylitis (inflammation of the spine).
==== Biological control ==== The EPA of New Zealand approved the release of Limenitis glorifica butterflies in 2013 as a biological control for Lonicera japonica. This butterfly is host specific for Japanese honeysuckle, but it may incidentally feed on other closely related plants, including Himalayan honeysuckle Leycesteria formosa. Oberea shirahatai is a Japanese honeysuckle host-specific beetle that feeds on the stems and leaves of Japanese honeysuckle. It was released in New Zealand in 2018 as another L. japonica-specialist biological control.
Sources: en.wikipedia.org
==== 8 April ==== In Iran, the Lavan Oil Refinery, located on Lavan Island was struck at around 10 a.m.; a fire ignited. The Iranian authorities denounced the event and stated that it was an act of "cowardice" by the "enemies". Israel denied being involved in the attack. The debris of a drone shot down by Iranian forces killed a 7-year-old child and injured another six members of the child's family in the town of Shushtar in Khuzestan province.
Blood for transfusion is obtained from human donors by blood donation and stored in a blood bank. There are many different blood types in humans, the ABO blood group system, and the Rhesus blood group system being the most important. Transfusion of blood of an incompatible blood group may cause severe, often fatal, complications, so crossmatching is done to ensure that a compatible blood product is transfused. Other blood products administered intravenously are platelets, blood plasma, cryoprecipitate, and specific coagulation factor concentrates.
1999: Established first quantifiable measurement of atractyloside in whole blood with high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS); 2001: GC-MS method required derivitization to detect atractyloside fragments; 2004: LC-MS (EI) using Waters Thermabeam detector resulted in complete fragmentation of the molecule; gentler ionization technique (ESI) was successfully used to detect ATR after chromatographic separation; 2006: Further development of procedure with ESI, eluent composition, and other experimental conditions, though still lacking specificity for forensic science. The procedure by Carlier et al. uses high-performance liquid chromatography coupled with high-resolution tandem mass spectrometry (HPLC-HRMS/MS). After the extraction of ATR and CATR from the blood or urine sample, separation was performed by reverse-phase HPLC. The MS detection used a quadrupole-orbitrap high-resolution detector after heated electrospray in negative ionization mode. These extraction techniques yielded 71.1% and 48.3% of ATR and CATR, respectively, in which these results met acceptable international criteria for forensic science: precision (≤15% or ≤20% at the LLOQ) and accuracy (between 80 and 115% or 80-120% at the LLOQ). For reference, additional sources have fully characterized atractyloside in NMR, MS, IR, etc.
The incidents began in Jaramana at approximately 2:00 a.m. on 28 April 2025, when an unidentified group opened fire on a local militia checkpoint near the "Al-Naseem" intersection at the entrance of Jaramana. Gunfire continued and intensified around 4:00 a.m., leading to the deaths of at least two members of the security forces and six residents of the city. Over ten others were injured in the initial wave of violence. Local factions imposed heightened security measures, erecting checkpoints and restricting movement into and out of the city. On 29 April 2025, clashes expanded to the Druze-majority towns of Sahnaya and Ashrafiyat Sahnaya. Armed groups attacked multiple security checkpoints using machine guns and RPGs. The fighting briefly paused, but continued after reinforcements arrived from Daraa. Hussam Waruar, the head of the Sahnaya Municipality, was killed along with his son on 1 May by unidentified gunmen. The unidentified groups killed the Druze leader, Wajdi al-Hajj Ali, who was shot in the head and died on 30 April 2025 before reaching the hospital.
(5.2.1) A sponsor may transfer any or all of the sponsor's trial-related duties and functions to a CRO, but the ultimate responsibility for the quality and integrity of the trial data always resides with the sponsor. The CRO should implement quality assurance and quality control. (5.2.2) Any trial-related duty and function that is transferred to and assumed by a CRO should be specified in writing. The sponsor should ensure oversight of any trial-related duties and functions carried out on its behalf, including trial-related duties and functions that are subcontracted to another party by the sponsor's contracted CRO(s). (5.2.3) Any trial-related duties and functions not specifically transferred to and assumed by a CRO are retained by the sponsor. (5.2.4) All references to a sponsor in this guideline also apply to a CRO to the extent that a CRO has assumed the trial-related duties and functions of a sponsor. Guidance from the US FDA published in 2013 also speaks to the responsibility of the sponsor to oversee work of the CRO, including the circumstance where risk-based monitoring has been delegated to the CRO. 2021 saw a major update to US FDA regulations related to providing the agency with information about CROs and how they "comply with FDA regulations".
Sources: en.wikipedia.org
=== Medical === Pentazocine is used primarily to treat pain, although its analgesic effects are subject to a ceiling effect. It has been discontinued by its corporate sponsor in Australia, although it may be available through the special access scheme.
Non-depolarizing neuromuscular blockers: Non-depolarizing agents act as competitive inhibitors for acetylcholine. Upon the binding of non-depolarizing neuromuscular blockers, neurotransmission is reduced. Consequently, depolarizing and muscle-contracting effects are decreased. Non-depolarizing neuromuscular blockers are generally reversible, and hence have no permanent effects on acetylcholine receptors.
The two types of beta decay are known as beta minus and beta plus. In beta minus (β−) decay, a neutron is converted to a proton, and the process creates an electron and an electron antineutrino; while in beta plus (β+) decay, a proton is converted to a neutron and the process creates a positron and an electron neutrino. β+ decay is also known as positron emission. Beta decay conserves a quantum number known as the lepton number, or the number of electrons and their associated neutrinos (other leptons are the muon and tau particles). These particles have lepton number +1, while their antiparticles have lepton number −1. Since a proton or neutron has lepton number zero, β+ decay (a positron, or antielectron) must be accompanied with an electron neutrino, while β− decay (an electron) must be accompanied by an electron antineutrino. An example of electron emission (β− decay) is the decay of carbon-14 into nitrogen-14 with a half-life of about 5,700 years:
The proton–proton chain is more prominent in stars the mass of the Sun or less. This difference stems from temperature dependency differences between the two reactions; pp-chain reaction starts at temperatures around 4×106 K (4 megakelvins), making it the dominant energy source in smaller stars. A self-maintaining CNO chain starts at approximately 15×106 K, but its energy output rises much more rapidly with increasing temperatures so that it becomes the dominant source of energy at approximately 17×106 K. The Sun has a core temperature of around 15.7×106 K, and only 1.7% of 4He nuclei produced in the Sun are born in the CNO cycle. The CNO-I process was independently proposed by Carl von Weizsäcker and Hans Bethe in the late 1930s. The first reports of the experimental detection of the neutrinos produced by the CNO cycle in the Sun were published in 2020 by the BOREXINO collaboration. This was also the first experimental confirmation that the Sun had a CNO cycle, that the proposed magnitude of the cycle was accurate, and that von Weizsäcker and Bethe were correct.
In 1800, France built Nautilus, a human-powered submarine designed by American Robert Fulton. They gave up on the experiment in 1804, as did the British, when they reconsidered Fulton's submarine design. In 1850, Wilhelm Bauer's Brandtaucher was built in Germany. It remains the oldest known surviving submarine in the world. In 1864, late in the American Civil War, the Confederate navy's H. L. Hunley became the first military submarine to sink an enemy vessel, the Union sloop-of-war USS Housatonic, using a gun-powder-filled keg on a spar as a torpedo charge. The Hunley also sank. The explosion's shock waves may have killed its crew instantly, preventing them from pumping the bilge or propelling the submarine. In 1866, Sub Marine Explorer was the first submarine to successfully dive, cruise underwater, and resurface under the crew's control. The design by German American Julius H. Kroehl (in German, Kröhl) incorporated elements that are still used in modern submarines. In 1866, Flach was built at the Chilean government's request by Karl Flach, a German engineer and immigrant. It was the fifth submarine built in the world and, along with a second submarine, was intended to defend the port of Valparaíso against attack by the Spanish Navy during the Chincha Islands War.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Reversed-phase HPLC gives the main purity figure, most often with UV detection near 214 nanometres. Mass spectrometry then confirms the molecular mass. Together the two methods distinguish a correct sequence from a closely related impurity.